High Speed ICG Ranibizumab AMD (08-EI-0103)

高速 ICG 雷珠单抗 AMD (08-EI-0103)

• 批准号: 8938361
• 负责人: Henry Wiley
• 金额: $ 5.09万
• 依托单位: NATIONAL EYE INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938361
• 关键词: Age related macular degeneration; Algorithms; Angiography; Area; Blindness; Choroidal Neovascularization; Computer software; Data; Elderly; Extravasation; Exudative age-related macular degeneration; FDA approved; Fluorescein; Frequencies; Fundus; Image; Indocyanine Green; Injection of therapeutic agent; Liquid substance; Measures; Membrane; Optical Coherence Tomography; Optics; Participant; Patients; Retinal; Speed; Structure; Structure of retinal pigment epithelium; Vascular Endothelial Growth Factors; Vision; Visual; base; design; hemodynamics; improved; inhibitor/antagonist; neovascular; novel; ranibizumab; response

ICG analysis of choroidal neovascularization in AMD treated with ranibizumab suggests that there is minimal effect on the actual choroidal neovascularization despite reduction in exudation. The preliminary one year results showed only a 5% change in the mean size of the choroidal neovascular membrane as graded with indocyanine green angiography. Minimal intensity projection OCT is a novel algorithm that identifies and displays the minimum optical intensity found between the internal limiting membrane and retinal pigment epithelium. The software was initially developed to provide an en face fundus image where fluid presented as dark regions. Surprisingly, bright areas were also noted and these seem to correspond to the outer retinal area overlying the choroidal neovascularization. The one year results showed a mean 6% increase in the area of outer retinal change noted with minIpOCT. These data suggest that anti-VEGF treatment in the form of ranibizumab has mininal effect on the culprit choroidal neovascularization itself. This provides useful data to assess other potential neovascular age related macular degeneration treatments. The study was closed in fiscal year 2014, based on a common termination date for all participants.

对使用雷尼比珠单抗治疗的AMD患者脉络膜新生血管的ICG分析表明，尽管渗出物减少，但对实际脉络膜新生血管的影响很小。初步的一年结果显示，吲哚青绿血管造影术分级的脉络膜新生血管膜的平均大小只有5%的变化。 最小强度投影OCT是一种新的算法，它识别并显示内界膜和视网膜色素上皮之间的最小光强度。该软件最初是为了提供面部眼底图像，其中液体呈现为黑色区域。令人惊讶的是，也发现了明亮的区域，这些区域似乎与脉络膜新生血管上方的视网膜外层区域相对应。一年的结果显示，minIpOCT记录的视网膜外部变化面积平均增加了6%。 这些数据表明，雷尼比珠单抗形式的抗血管内皮生长因子治疗对罪魁祸首脉络膜新生血管本身有微小的影响。这为评估其他潜在的新生血管年龄相关性黄斑变性治疗提供了有用的数据。 根据所有参与者的共同终止日期，这项研究于2014财年结束。